Kevin Kalinsky, MD, MS, of Glenn Family Breast Center, gives insight into the real-world data supporting the use of sacituzumab govitecan-hziy in the treatment of triple-negative breast cancer (TNBC).
Ahead of ESMO 2023, Kevin Kalinsky, MD, MS, of Glenn Family Breast Center, highlighted the important aspects of sacituzumab govitecan-hziy in the treatment of triple-negative breast cancer and the real-world data validating it as an effective standard-of-care option for affected patients.
This transcript has been lightly edited for clarity.
Transcript
Can you give an overview of sacituzumab govitecan-hziy in the treatment of triple-negative breast cancer?
Sacituzumab govitecan-hziy is an antibody-drug conjugate. So it's an antibody that is a linker that's attached to a payload. It has been approved for patients with triple-negative breast cancer, based upon the results of a large, randomized phase 3 trial called the Ascent study. We also have approval of sacituzumab govitecan-hziy for patients with endocrine-resistant, estrogen-driven HER2-negative metastatic breast cancer and that is also based upon a large randomized phase 3 trial called the TROPiCS-02 study. In both of these studies, sacituzumab govitecan-hziy was compared to physician-choice chemotherapy, and we saw overall survival benefits in both of those trials.
What are some highlights from the real-world data supporting this treatment as a standard-of-care option?
For our patients with metastatic triple-negative breast cancer, the approval of sacituzumab govitecan-hziy was the first antibody-drug conjugate to be approved in this disease type. One of the questions that we had was about how sometimes the clinical trial population doesn't always reflect what we see in the real world, and so that was the rationale for undergoing this analysis. What we saw was that what was reflected in the phase 3 trial is also seen in the real-world analysis that we did.
To be specific, we saw for patients who were treated with sacituzumab govitecan-hziy that the median real-world overall survival was about 14 months. For those who were treated later on, the overall survival was a little bit less: approximately 10 months or so. The drugs seemed to be well-tolerated with the adverse events that we would otherwise expect to see based upon the Ascent trial. But the other thing that's a bit important to just mention in terms of this analysis is that, approximately, a quarter of patients were identified as Black. We have seen in other studies, including the Ascent study, that the rate of underrepresented minorities can be underrepresented in these trials. And it was good to see that there was no impact on efficacy or tolerability across the diversity that was represented in our real-world analysis.
Integrating RECIST and Clinician Approaches Boosts NSCLC Research
May 8th 2024Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in observational studies were compared for their concordance and reliability.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
Integrating RECIST and Clinician Approaches Boosts NSCLC Research
May 8th 2024Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in observational studies were compared for their concordance and reliability.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
2 Commerce Drive
Cranbury, NJ 08512